Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Equities research analysts at Piper Jaffray Companies issued their Q1 2021 EPS estimates for shares of Rocket Pharmaceuticals in a research note issued on Thursday, November 7th. Piper Jaffray Companies analyst T. Van. Buren expects that the biotechnology company will earn ($0.70) per share for the quarter. Piper Jaffray Companies currently has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Rocket Pharmaceuticals’ Q2 2021 earnings at ($0.75) EPS and Q3 2021 earnings at ($0.80) EPS.
A number of other brokerages also recently commented on RCKT. Cowen reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Thursday. ValuEngine downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Oppenheimer reduced their price objective on Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, William Blair restated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.33.
Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.11.
A number of large investors have recently bought and sold shares of RCKT. Lindbrook Capital LLC raised its position in Rocket Pharmaceuticals by 200.0% in the third quarter. Lindbrook Capital LLC now owns 3,000 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 2,000 shares during the period. Bank of Montreal Can purchased a new stake in Rocket Pharmaceuticals in the second quarter valued at $38,000. Tower Research Capital LLC TRC raised its position in Rocket Pharmaceuticals by 1,107.4% in the third quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,898 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in Rocket Pharmaceuticals in the second quarter valued at $86,000. Finally, Meeder Asset Management Inc. purchased a new stake in Rocket Pharmaceuticals in the third quarter valued at $88,000. Institutional investors own 96.72% of the company’s stock.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
Further Reading: How to trade on quiet period expirations
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.